Nautilus Q1 net loss $16.6M, operating expenses down 13% YoY

Nautilus Biotechnology, Inc.

2025-Q1 EPS reported -$0.13

Net loss $16.6M, improved from $18.7M in Q1 2024.
Operating expenses $18.8M, down 13% from $21.6M prior year.
Cash, equivalents, and investments $192.8M as of March 31, 2025.
CEO reports progress on Tau proteoform assay toward commercial launch.

item 2.02 item 9.01

Nautilus Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001808805-25-000039

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.